JACKSONVILLE, Fla. (April 25, 2019) – Novo Nordisk is the 2019 recipient of the American College of Endocrinology (ACE) Philanthropy Award. The award was announced during AACE 2019, the American Association of Clinical Endocrinologists’ 28th Annual Scientific & Clinical Congress in Los Angeles.
The ACE Philanthropy Award is presented to an organization that has made significant charitable contribution to ACE or provided funding for an ACE program. AACE membership not required.
Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. Headquartered in Denmark, the company employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk discovers and develops innovative medicines and makes them accessible to patients throughout the world. The company’s portfolio includes products and delivery systems for diabetes care and other chronic conditions, such as rare bleeding disorders, growth hormone related disorders and obesity.
Building on this year’s theme, Get Inspired, the AACE 28th Annual Scientific & Clinical Congress highlights include:
90+ national and international speakers from leading hospitals, health systems and private practices
80+ sessions covering the hottest topics and best practices around endocrinology and its eight primary disease states: adrenal, thyroid, bone, diabetes, lipids, obesity, pituitary and reproductive
2,000+ attendees from 35+ countries, including physicians and allied healthcare professionals, physician assistants, nurse practitioners, certified diabetes educators and others
Nearly 500 posters and abstracts featuring innovative research, clinical trials and case studies
100+ exhibitors and sponsors showcasing the latest products, technologies and services for the endocrinology field
AACE is the world’s largest organization that represents clinical endocrinologists, with over 7,000+ members in the United States and 97 other countries. Advanced online registration is open until April 9, 2019.